Terbium-149 for nuclear medicine. The production of 149Tb via heavy ions induced nuclear reactions

Zaitseva, N.G.; Dmitriev, S. N.; Maslov, O. D.; Molokanova, L. G.; Starodub, G. Ya.; Шишкин, С. В.; Shishkina, T. V.; Beyer, G.J.

doi:10.1007/s10582-003-0058-z

Cited by 22 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the possibility of using 12 C 15,18 beams and other heavy ions 23 to produce 149 Tb, was repeatedly considered. In this case, both a direct way to obtain by the reaction 141 Pr( 12 C,4n) 149 Tb is possible, as well as an indirect one: 142 Nd( 12 C,5n) 149 Dy → 149 Tb.…”

Section: Discussionmentioning

confidence: 99%

“…The latter looks more promising. According to Zaitseva et al 15 , this way can yield tens of GBq for irradiation at a beam current of 50-100 μA. Upon 1.25 hours irradiation of 12 mg/cm 2 thick natural neodymium target with a beam of 12 C ions with an energy of 108 MeV and a particle current of 1 μA 2.6 MBq of 149 Tb were produced.…”

Section: Discussionmentioning

confidence: 99%

“…Various reactions have been proposed for the production of 149 Tb, in particular, under the action of protons 14 and heavy ions [15][16][17] (Table 1); a review can be found in [18][19][20] . However, the production of this radionuclide is associated with serious difficulties.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Moiseeva

Алиев

Унежев

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Method for production of alpha emitter 149 tb by irradiation of 151 Eu with 70 MeV 3 He nuclei is proposed. For the first time, the cross sections for the formation of isotopes 149,150,151,152 Tb were measured experimentally using a stack foil technique in the 3 He particles energy range 70 → 12 MeV. The thick target yield of 149 Tb is 39 MBq/μAh, or 230 MBq/μA 149 tb at saturation. the optimal energy range from the point of view of radioisotopic purity is 70 → 40 MeV. At these conditions about 150 MBq/μA 149 Tb can be produced in 8 hours irradiation, which is sufficient for therapeutic applications. The main impurities are 150 Tb (~100% in activity) and 151 Tb (~30% in activity). The proposed method surpasses its counterparts by the high content of the target isotope in the natural mixture and the simplicity of the radiochemical separation of 149 tb from the bulk target material.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Moiseeva

Алиев

Унежев

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even if the indirect route showed more interesting yields than the direct one, production yields and radiochemical purity reported were very low in comparison with the two first routes mentioned. Besides, the availability of accelerators equipped with a 12 C-ion beam is quite limited [ 267 , 271 , 272 ].…”

Section: Terbium-149mentioning

confidence: 99%

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

et al. 2021

View full text Add to dashboard Cite

Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.

show abstract

“…A few examples would be helpful to visualize the concept of a "matched pair." So-called matched pairs or theranostic pairs include: 43/44 Sc- 47 Sc, 64 Cu-67 Cu, 72 As- 77 As, 83 Sr-89 Sr, 86 Y-90 Y, 124 I-131 I, 203 Pb-212 Pb, etc. (5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application

Naskar

Lahiri

2021

Front. Med.

View full text Add to dashboard Cite

Currently, research on terbium has gained a momentum owing to its four short-lived radioisotopes, 149Tb, 152Tb, 155Tb, and 161Tb, all of which can be considered in one or another field of nuclear medicine. The members of this emerging quadruplet family have appealing nuclear characteristics and have the potential to do justice to the proposed theory of theranostics nuclear medicine, which amalgamates therapeutic and diagnostic radioisotopes together. The main challenge for in vivo use of these radioisotopes is to produce them in sufficient quantity. This review discusses that, at present, neither light charged particle nor the heavy ion (HI) activation are suitable for large-scale production of neutron deficient terbium nuclides. Three technological factors like (i) enrichment of stable isotopes to a considerable level, (ii) non-availability of higher energies in commercial cyclotrons, and (iii) non-availability of the isotope separation technique coupled with commercial accelerators limit the large scale production of terbium radionuclides by light charged particle activation. If in future, the technology can overcome these hurdles, then the light charged particle activation of enriched targets would produce a high amount of useful terbium radionuclides. On the other hand, to date, the spallation reaction coupled with an online isotope separator has been found suitable for such a requirement, which has been adopted by the CERN MEDICIS programme. The therapeutic 161Tb radionuclide can be produced in a reactor by neutron bombardment on enriched 160Gd target to produce 161Gd which subsequently decays to 161Tb. The radiochemical separation is mandatory even if the ISOL technique is used to obtain high radioisotopic purity of the desired radioisotope.

show abstract

Terbium-149 for nuclear medicine. The production of 149Tb via heavy ions induced nuclear reactions

Cited by 22 publications

References 6 publications

Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Cross section measurements of 151Eu(3He,5n) reaction: new opportunities for medical alpha emitter 149Tb production

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application

Contact Info

Product

Resources

About